NIFEdipine (redirected from Nu-Nifed)

nifedipine /ni·fed·i·pine/ (ni-fed´ĭ-pēn) a calcium channel blocking agent used as a coronary vasodilator in the treatment of coronary insufficiency and angina pectoris; also used in the treatment of hypertension.

---

ni·fed·i·pine (n-fd-pn)

n.

A coronary vasodilator and calcium-channel blocking agent that reduces calcium ions available to heart and smooth muscle, used in the treatment of angina pectoris.

---

NIFEdipine

[nifed′ipēn]

a calcium channel blocker.

indications It is prescribed for the treatment of vasospastic and effort-associated angina, pulmonary hypertension, and hypertension (sustained-release form only).

contraindications Known hypersensitivity to this drug prohibits its use, and immediate-release forms should not be used to treat hypertension. The practice of using short-acting sublingual nifedipine in hypertensive emergencies or pseudoemergencies is dangerous and should be abandoned.

adverse effects Among the more serious adverse effects are hypotension, peripheral edema, palpitations, dyspnea, nausea, dizziness, flushing, and headache. When given sublingually, stroke, severe hypotension, syncope, heart block, sinus arrest, myocardial infarctions, and fetal distress are among the adverse effects reported.

---

nifedipine (nīfed´pēn´),

n brand names: Procardia, Procardia XL;
drug class: calcium channel blocker;
action: inhibits calcium ion influx across cell membrane during cardiac depolarization; produces relaxation of coronary vascular smooth muscle, dilates coronary arteries; increases myocardial oxygen delivery in patients with vasospastic angina; dilates peripheral arteries;
uses: chronic stable angina pectoris, vasospastic angina, hypertension. Can cause gingival hyperplasia.

---

nifedipine

a calcium channel blocker used principally as a vasodilator.

---

nifedipine

Adalat CC, Adalat PA (CA), Adalat XL (CA), Adipine (UK), Afeditab CR, Angiopine (UK), Apo-Nifed (CA), Calchan (UK), Cardilate MR (UK), Cordacten (UK), Fortipine (UK), Gen-Nifedical (CA), Hypolar Retard (UK), Nifediac CC, Nifedical XL, Nifedipress (UK), Nifopress (UK), Novo-Nifedin (CA), Nu-Nifed, Procardia, Procardia XL, Slofedipine (UK), Tensipine (UK)

Pharmacologic class: Calcium channel blocker

Therapeutic class: Antianginal, antihypertensive

Pregnancy risk category C

Action

Inhibits calcium transport into myocardial and vascular smooth muscle cells, suppressing contractions. Dilates main coronary arteries and arterioles and inhibits coronary artery spasm, increasing oxygen delivery to heart and decreasing frequency and severity of angina attacks.

Availability

Capsules: 5 mg, 10 mg, 20 mg

Tablets (extended-release): 10 mg, 20 mg, 30 mg, 60 mg, 90 mg

⊘Indications and dosages

➣ Vasospastic (Prinzmetal's) angina; chronic stable angina

Adults: Initially, 10 mg P.O. (immediate-release) t.i.d. titrated over 7 to 14 days; usual effective range is 10 to 20 mg t.i.d., not to exceed 180 mg/day. Patient may be switched to extended-release at nearest equivalent of immediate-release daily dosage (for instance, 30-mg immediate-release dose may be switched to 90-mg extended-release dose). Total extended-release dosage should not exceed 90 mg/day.

➣ Hypertension

Adults: 30 to 60 mg/day P.O. (extended-release only) titrated over 7 to 14 days to a maximum of 120 mg/day

Off-label uses

• Aortic regurgitation
• Heart failure
• Migraine
• Prevention of labor

Contraindications

• Hypersensitivity to drug

Precautions

Use cautiously in:
• chronic renal insufficiency
• hypotension, aortic stenosis, heart failure, significant left ventricular dysfunction (especially when used with beta-adrenergic blockers), peripheral edema
• elderly patients
• pregnant or breastfeeding patients (safety not established)
• children (safety not established).

Administration

• Give immediate-release form with or without food. If GI upset occurs, give with meals, but never with grapefruit or grapefruit juice.
• Don't crush or break extended-release tablet. Make sure patient swallows it whole. Give on empty stomach, and not with grapefruit or grapefruit juice.
• Know that Procardia XL and Adalat CC are not equivalent because of their pharmacokinetic differences.
• Be aware that only extended-release tablets are used to treat hypertension.

Route	Onset	Peak	Duration
P.O.	20 min	Unknown	6-8 hr
P.O. (Adalat PA)	Unknown	4 hr	12 hr
P.O. (Adalat CC, PA, XL)	Unknown	6 hr	24 hr

Adverse reactions

CNS: headache, dizziness, fatigue, asthenia, paresthesia, vertigo

CV: peripheral edema, chest pain, hypotension

EENT: epistaxis, rhinitis

GI: nausea, constipation

GU: urinary frequency, erectile dysfunction

Musculoskeletal: leg cramps

Skin: flushing, rash

Interactions

Drug-drug. Beta-adrenergic blockers: increased risk of heart failure, severe hypotension, or angina exacerbation

Cimetidine: increased nifedipine blood level

Coumarin anticoagulants: increased prothrombin time

Digoxin: increased risk of digoxin toxicity

Quinidine: decreased quinidine blood level

Drug-diagnostic tests. Antinuclear antibody, direct Coombs' test: false-positive results

Drug-food. Grapefruit, grapefruit juice: increased nifedipine blood level and effects

Drug-herbs. Ephedra (ma huang), yohimbine: antagonism of nifedipine effect

Ginkgo, ginseng: increased nifedipine blood level

St. John's wort: decreased nifedipine blood level

Drug-behaviors. Alcohol use: additive hypotension

Patient monitoring

• Monitor vital signs and cardiovascular status. Stay alert for chest pain and edema.
• Watch for rash.

Patient teaching

• Tell patient he may take immediate-release form with or without meals. If GI upset occurs, tell him to take it with meals, but never with grapefruit or grapefruit juice.
• Caution patient not to crush or break extended-release tablets. Tell him to swallow them whole. Advise him to take on empty stomach, and not with grapefruit or grapefruit juice.
• Inform patient that angina attacks may occur 30 minutes after a dose. Explain that these attacks are usually temporary and don't mean that drug should be withdrawn.
☞ Tell patient to report rash immediately.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, balance, and alertness.
• Instruct patient to consult prescriber before taking herbs or over-the-counter drugs (especially cold remedies).
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

---

nifedipine

Procardia^® Cardiology A dihydropiridine CCB vasodilator used for angina, as a short-acting antihypertensive–↓ BP, resulting in a ↓ left ventricular volume and myocardial mass, ↑ ejection fraction Side effects Tachycardia, headache, peripheral edema, cerebral ischemia, stroke, severe hypotension, AMI, conduction defects, fetal distress, death. See Calcium channel blockers, Hypertension, TIBBS.